CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Albumin-bound paclitaxel

First Posted Date: 2006-11-10

Last Posted Date: 2019-11-22

Lead Sponsor: Celgene

Target Recruit Count: 67

Registration Number: NCT00398086

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Scottsdale Healthcare/Virginia Pipe Cancer Institute, Scottsdale, Arizona, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Ctr, Birmingham, Alabama, United States

and more 2 locations

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Phase 1

Completed

Conditions: Lymphomas
Cancer

Interventions: Drug: NPI-0052

First Posted Date: 2006-11-08

Last Posted Date: 2017-11-22

Lead Sponsor: Celgene

Target Recruit Count: 51

Registration Number: NCT00396864

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Univ. of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Premiere Oncology of America, Scottsdale, Arizona, United States

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Adriamycin and Cytoxan (AC)
Drug: ABI-007
Drug: Taxol
Drug: Bevacizumab
Drug: pegfilgrastim

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 197

Registration Number: NCT00394251

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: ABI-007
Drug: Bevacizumab

First Posted Date: 2006-10-31

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 50

Registration Number: NCT00394082

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Amrubicin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2006-10-17

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 99

Registration Number: NCT00388960

Locations: 🇳🇱
Academisch Medisch Centrum, Amsterdam, Netherlands
🇳🇱
Medisch Spectrum Twente - Dept of Pulmonary Diseases, Enschede, Netherlands
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

and more 22 locations

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Phase 2

Withdrawn

Conditions: Metastatic Breast Cancer

First Posted Date: 2006-09-27

Last Posted Date: 2008-09-23

Lead Sponsor: Celgene Corporation

Target Recruit Count: 66

Registration Number: NCT00380835

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Romidepsin
Drug: Gemcitabine

First Posted Date: 2006-09-22

Last Posted Date: 2019-10-30

Lead Sponsor: Celgene

Target Recruit Count: 36

Registration Number: NCT00379639

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Amrubicin

First Posted Date: 2006-09-12

Last Posted Date: 2019-10-24

Lead Sponsor: Celgene

Target Recruit Count: 75

Registration Number: NCT00375193

Locations: 🇺🇸
Texas Oncology, P.A., Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Medical Oncology Associates, Kingston, Pennsylvania, United States
🇺🇸
SUNY Upstate Medical Center, Syracuse, New York, United States

and more 43 locations

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Amrubicin
Drug: Topotecan

First Posted Date: 2006-04-27

Last Posted Date: 2009-09-30

Lead Sponsor: Celgene Corporation

Target Recruit Count: 76

Registration Number: NCT00319969

Locations: 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸
Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States
🇺🇸
Hematology/Oncology Consultants, St. Louis, Missouri, United States

and more 43 locations

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms
Neoplasm Metastasis

Interventions: Drug: ABI-007 (Abraxane)
Drug: bevacizumab

First Posted Date: 2006-01-25

Last Posted Date: 2019-11-22

Lead Sponsor: Celgene

Target Recruit Count: 208

Registration Number: NCT00281528

Locations: 🇺🇸
Medical Oncology Aultman Hospital, Canton, Ohio, United States
🇺🇸
Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 37 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy